This article was originally posted on Dec. 14.

Qiagen said this week that it has completed its $90 million, all-cash acquisition of SABiosciences, a privately held developer of disease- and pathway-focused PCR assay panels.

Peer Schatz, CEO of Qiagen, said in a statement that he believes the integration of the 100-employee, Frederick, Md.-based company into its operations will be "a quick and smooth one," citing the "high level of complementarities" between the firms.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.